Physician profile
Michael Brown
NPI 1760746515
$4,703.87
in general payments reported to CMS, 2019-2025
32 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $714 · 2023: $1,004 · 2024: $943 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,468.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $483.81 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $391.98 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $329.68 | 2023-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $321.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.54 | 2023-2025 | Breztri, Farxiga |
| Boston Scientific Corporation | $240.19 | 2024-2025 | Wavewriter Alpha Prime 16, Intracept |
| Regeneron Healthcare Solutions, INC. | $227.08 | 2023-2024 | Dupixent |
| Exact Sciences Corporation | $220.92 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.99 | 2025 | Jardiance |
| Amgen INC. | $163.97 | 2023-2025 | Otezla, Otezla |
| Neurocrine Biosciences, INC. | $128.56 | 2025 | |
| Janssen Pharmaceuticals, INC | $127.38 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Corium, LLC | $125.00 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $124.49 | 2022 | |
| Insulet Corporation | $123.94 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.91 | 2021 | |
| Stryker Corporation | $103.22 | 2023-2025 | Stryker |
| Novo Nordisk INC | $102.92 | 2025 | Ozempic |
| Neurelis, INC. | $86.57 | 2023 | Valtoco |
| Dynavax Technologies Corporation | $80.83 | 2024 | Heplisav-B |
| Gilead Sciences, INC. | $80.79 | 2024 | Epclusa |
| Glaxosmithkline, LLC. | $80.50 | 2022 | |
| Genzyme Corporation | $76.10 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $66.68 | 2024 | Inpefa |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
| Alkermes, INC. | $51.54 | 2021 | |
| Evofem Biosciences, INC. | $49.91 | 2022 | |
| Lucid Diagnostics INC. | $21.42 | 2025 | |
| Genentech USA, INC. | $13.62 | 2023 | Tnkase |
| Pharmacyclics LLC, An Abbvie Company | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.